We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Open Orphan Plc | ORPH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.00 | 10.00 |
| Top Posts |
|---|
Posted at 20/10/2022 09:52 by plasybryn Good post on RBD - Cathal Friel essentially set up Open Orphan (ORPH) which is about to change it's name to HVivo which is one of the parts of the company. He has brought the company to profitability from the original loss making HVivo that he acquired.He promised the earth and the share price hit 47p, but so far he has only delivered manure and the share price is now 10p'ish.He did buy a huge chunk of shares at about 27p I think, so he is well down on his own investment.He clearly wants to deliver shareholder value and I doubt he is one for asset stripping a company, but he has failed to deliver many of his promises over the past 2 years or so.They managed to list an asset that the company owned and created Poolbeg (POLB) which is looking to acquire early stage drugs or delivery systems and develop them and sell on. Was listed at 10pps with a 9 month lock-in, share price now about 7p but dropped as low as 4.5p. That one could be a winner. |
Posted at 14/10/2022 22:56 by goforgold1 Someone asked the question on DVRG another scam of a company run by an Irish man . The answer was yes it's 3p now . Same MO as ORPH . Very very strange . Both with the Richardson connection . Both these stacks have been primed to go bust and being shorted from about price area of 35p each . ORPH is now being investigated it will all come out in a few years to come or you will get a whistleblower. |
Posted at 12/10/2022 18:01 by sillyussoddus You're a bit of a numpty really. The connection between DVRG and ORPH and all sorts of other failed BOD folk has been talked about for years.Never mind, both of the CEO's will no doubt turn up with another new fangled mashup of some companies and float again. Then you can all make the same mistakes again. What fun ! At least ORPH has a genuine business and isn't making it up as it goes along. The comedian (although its not funny really) at DVRG had a very chequered history compared to CF, although clearly both financial 'operators', with no real interest in their products. |
Posted at 06/10/2022 13:31 by burtond1 Contracts, Revenue, Cash in the Bank and now an exciting new look for Open Orphan say @TMSreach "...A company recording impressive revenue growth is Open Orphan. Its flexible challenge test model continues to secure new contracts for the treatment of an ever wider range of diseases. At this low price ORPH is one to watch this autumn and into the new year and remember to find the company under the HVO ticker after 26 October..."https://tot |
Posted at 09/9/2022 09:36 by bobsworth Off to Wales for the TW event tomorrow. Snap shot of questions I hope to ask Cathal ? Dim timeframes? ? Plans for the £20m cash? ? Are you happy with the EBITA margins? ? With zero competition & mega savings enjoyed by big Pharma should we not be charging more for HCS? ? Thoughts on the beleaguered share price? ? Is the share price being controlled by a dominant seller? ? If not why does he think folks are selling? ? Hivo/Merger & listing on the Nasdaq? ? Dividend, when? ? Institutions not buying, why? ? Name change to Hivo! Why now? ? Latest pleas on Imutex and Biopharma? ? Do you read the Telegram ORPH BB? ? Do you regret saying Sp will rise 50% every 6 months ? ? Do you regret buying shares at 26p ? ? Have we got a persistent big seller & if so who is it? ? Why have you been so silent on ORPH recently ? Do you trust TW? ? What's the minimum price you would sell Hivo for? ? Have you spoken to Apple Watch about Dim and If so are they interested in paying a license fee for its health data? ? What's the hold up on monetising the data ? How can Dim function without Hivo if it's spun out? ? Where do you see yourself in 1 years time, 2 years time & 3 years time??On my way ? |
Posted at 25/8/2022 11:45 by nathanr999 If I recall correctly, poolbeg have access options on the DIM data for only an initial Limited period without cost. One imagines if they want to access data post that expiry it will be pay to.play. Other biotechs may also in future choose to.pay to play- we need to hear more on this no doubt to see where the value is developing. Adding corona models, malaria models widens data available. At some point a company will choose to pay to see or utilise this and a new high margin revenue stream will develop. Orph is still a young company and I am not sure Hvivo really exploited what they had effectively as it seems a lot of distraction and capital was burnt trying to develop drug assets rather than the service side which is unique in the market. Lots of biotechs develop or try to develop drugs with variable success but the challenge study service is a leader and repeatable with minimal risk vs drug development. Orph will have run more challenge studies in 22/23 then hvivo did in 2/3 years prior to acquisition. The drug assets the Hvivo still exist and may yet generate revenue for us but biotech market is shot to pieces. Good companies with real quality assets struggling for capital ala 4d and shield and have led them to collapse or be reliant on onerous terms. As the acceptance of challenge models increases and more companies want them them price to do can be marched upwards improving margins. No one else has multiple variants of corona,multiple flu models and rsv to offer. CHIMS are still relatively rare in drug approval process but we can see the progress being accelerated in size and frequency. Liberum target is very Conservative but fair for now but likely will rise close to finncap as we move forward.The biotech market will turn and become more favourable, upping valuation metrics and capital raising will increase -that will make prep and imutex asset sales.more attractive. It will also allow young biotechs to access more capital to fund their assets through challenge studies. Happy to patiently wait here and I will see really decent returns even when factoring opportunity costs holding for 3 to 5 years. Acquisition of orph or hvivo business unit a high probability and will be many multiples of current price. |
Posted at 25/8/2022 08:43 by rivaldo I'll repeat my earlier post as jansky61 evidently missed it.....Liberum have initiated coverage on ORPH today with a Buy and 21.6p price target. Their note is 62 pages long! The opening summary paragraph is: "Open Orphan is the global leader in challenge study CRO services, a small but growing pharmaceutical services segment. Sales are set to grow 27% this year, it is profitable and cash generative, has an current order book at >£80m and £15.4m of net cash (pre-IFRS16). Yet amongst investors it is largely unknown. In our view, Open Orphan offers investors a growth story in a defensive sector at an attractive entry point. Shares trade on an undemanding 7x 2023 EV/EBITDA and a 5.8% FCF yield, 60-80% below UK listed peers. This discount should narrow as growth is delivered, the track record extends, and investor awareness grows. We initiate with a BUY rating and a 21.60p TP." |
Posted at 25/8/2022 08:31 by rivaldo Liberum have initiated coverage on ORPH today with a Buy and 21.6p price target.Their note is 62 pages long! The opening summary paragraph is: "Open Orphan is the global leader in challenge study CRO services, a small but growing pharmaceutical services segment. Sales are set to grow 27% this year, it is profitable and cash generative, has an current order book at >£80m and £15.4m of net cash (pre-IFRS16). Yet amongst investors it is largely unknown. In our view, Open Orphan offers investors a growth story in a defensive sector at an attractive entry point. Shares trade on an undemanding 7x 2023 EV/EBITDA and a 5.8% FCF yield, 60-80% below UK listed peers. This discount should narrow as growth is delivered, the track record extends, and investor awareness grows. We initiate with a BUY rating and a 21.60p TP." |
Posted at 15/7/2022 15:37 by sikhthetech There you go, evidence of marvelman's BS..The clueless Marvelman, from 10months ago... same old BS and twisting and manipulation as he is doing now... whilst the Orph mcap has crashed as I predicted.. down 60%.. Marvelman must have lost a fortune here over the year, hence why he's bitter ..lol well at least finncap have increased their target price from over a year ago... oh wait.. ;-) sikhthetech - 20 Sep 2021 - 15:42:37 - 18835 of 20224 open orphan a new beginning Marvel, Why you ignoring the question on fundamentals? I'm sure readers would like to know. What's the high level of 'accrued expenses and deferred income' with Orph then??? How does that compare to the amount of cash. lol Finncap, company broker, have also downgraded Orph to 44p from 47p. Odd, given it's supposed to be significant growth ahead. You're also twisting my post. I compared them on fundamentals with TLY's £113m revenue, £14.7m cash, dividend paying ... I never said they are the same business models. You're clearly rattled that readers might realise that Orph at £160m is overvalued when comparing the fundamentals with TLY. |
Posted at 01/7/2022 11:21 by m5 Here you go."Open Orphan" or the "Company") GBP14.7m influenza contract signed Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan plc, has signed a GBP14.7m contract for an influenza characterisation study and a follow on influenza human challenge study with an existing top five global pharmaceutical client. Revenue from the contract will be recognised across 2022 and 2023. This follows a challenge virus manufacturing contract signed with the same client, announced on 4 May 2022. Following completion of the challenge agent manufacturing, the characterisation study will identify a dose of the flu challenge agent that causes a safe and reliable infection in healthy volunteers. The study, which is sponsored by hVIVO, is expected to start in Q3 2022, subject to the relevant regulatory approvals, and will enrol volunteers recruited from the Company's clinical trial volunteer recruitment arm, FluCamp . As part of the study, hVIVO Labs will develop and validate challenge agent specific assays for the new flu challenge agent to US Food and Drug Administration (FDA), European Medicines Agency (EMA) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) standards. This includes quantitative polymerase chain reaction (qPCR) for viral load determination, viral infectivity assay and serological assays for antibody level determination. Following completion of the characterisation study, hVIVO will conduct a human challenge study, expected to commence in Q1 2023. The study will enable the Company to determine the efficacy of a number of different vaccine candidates for the reduction in incidence of symptomatic flu infection and disease severity in healthy volunteers. This will help select which of the candidates to progress further into later stage clinical trials. The vaccine study can be initiated, subject to receipt of the relevant regulatory approvals, as soon as the Company completes the infectivity and safety data review from the characterisation study and establishes the best challenge agent dose for safe volunteer inoculation. Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said: "This is another important milestone for hVIVO in that, in addition to the previously announced manufacture of a bespoke challenge agent, we have now been contracted to conduct the characterisation and the challenge studies with this big pharma customer. Moreover, we will also be providing full recruitment and laboratory services. This highlights hVIVO's unique full-service offering in running complex human challenge studies. Our team has a long history of manufacturing challenge agents and conducting human challenge studies. In regard to challenge studies our experience is unrivalled, our scientific expertise unmatched, and our operational delivery in a class of its own." Alex Mann, Senior Director of Clinical Science of hVIVO, Sponsor Representative and Scientific Design Lead, commented: "This major contract win solidifies hVIVO's position in the market in offering the full spectrum of support to clients, from start to finish of the vaccine and drug discovery process. Furthermore, the development of challenge agent specific assays underlines the skill and expertise of our experienced lab scientific team to validate bespoke assays to international standards for use in good clinical practice (GCP) clinical trials. The threat of influenza has never been greater, with an estimated one billion cases per year. Our continued work to support our clients' vaccine and antiviral programme's will support the quick, efficient and cost-effective development of these lifesaving medicines." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
